Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

BACKGROUND: We have previously published initial efficacy of the indoleamine 2,3-dioxygenase (IDO)/anti-programmed death ligand 1 (PD-L1) vaccine in combination with nivolumab in 30 anti-PD-1 therapy naïve patients with metastatic melanoma (cohort A). We now report long-term follow-up of patients in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorentzen, Cathrine Lund, Kjeldsen, Julie Westerlin, Ehrnrooth, Eva, Andersen, Mads Hald, Marie Svane, Inge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230976/
https://www.ncbi.nlm.nih.gov/pubmed/37217243
http://dx.doi.org/10.1136/jitc-2023-006755

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230976/
https://www.ncbi.nlm.nih.gov/pubmed/37217243
http://dx.doi.org/10.1136/jitc-2023-006755

Ejemplares similares